Negotiable: Paramount Recruitment: Bioinformatics Engineer - Boston Precision Medicine, Cancer Genomics, Software Engineering, Bioinformatician A world-renowned institute in Boston Boston, Massachusetts

Funding Opportunity RFA-HD-19-025 from the NIH Guide for Grants and Contracts. The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) invites applications from investigators willing to participate with the NICHD + others for an observational clinical study of infants born to mothers who are exposed to prenatal opioids. The public health opioid epidemic has a significant effect on infants who were exposed prenatally to opioids. This funding opportunity announcement (FOA) is intended to support multi-site clinical research devoted to investigating the impact of prenatal opioid exposure on infant outcomes as well as neuroimaging in opioid exposed versus unexposed newborns. The objective of this program is to advance scientific research that facilitates knowledge and care for infants exposed in utero to opioids. This program benefits the public: infants and families with opioid exposure and their health care providers. This FOA supports trials that require participation of two or more collaborative sites for completion of the study. Accordingly, the collaborating sites develop a specific protocol across the sites and are organized to increase sample size, accelerate recruitment, or increase sample diversity and representation. Each site has its own Program Director/Principal Investigator (PD/PI) and each consortium includes a mechanism for coordination, implementation and monitoring of the protocol across sites, quality control, database management, statistical analysis, and reporting. Public Law 115-141, the Consolidated Appropriations Act of 2018 (signed on March 23, 2018) includes a requirement that grantees from for-profit applicant organizations must provide a 50% match and/or in-kind contribution of all federally awarded dollars under the grant award (direct costs, as well as facilities and administrative costs) for research related to opioid addiction, development of opioid alternatives, pain management and addiction treatment.

Funding Opportunity RFA-NS-19-018 from the NIH Guide for Grants and Contracts. HEAL Initiative: This is a HEAL Initiative UH3 FOA that will solicit device applications to treat pain.

Funding Opportunity RFA-NS-19-017 from the NIH Guide for Grants and Contracts. HEAL Initiative: This is a HEAL Initiative U44 FOA that will solicit applications for devices to treat pain. There will be a Fast-track and Direct to Phase 2 Option.

Funding Opportunity RFA-EB-18-003 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support preclinical development and demonstration of safe, effective, and non-addictive device-based technologies and approaches to treat pain. The goal of the program is to demonstrate treatment using credible neural targets for device-based interventions and/or diagnostics for pain, building upon the latest mechanistic knowledge about the anatomy and physiology of central, spinal, and peripheral pathways involved in pain. Awarded activities will facilitate the translation of new devices up to the stage of readiness for first in human (FIH) clinical trials by overcoming key challenges identified during preliminary proof-of-concept studies. The scope of the program includes technology development and optimization, and studies to prepare for approvals for human use. This is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in the development of the project plan and monitoring of research progress.

Funding Opportunity RFA-NS-19-025 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to invite applications for the Specialized Clinical Centers (hubs) of the Early Phase Pain Investigation Clinical Network (EPPIC-Net). EPPIC-Net will serve as the cornerstone of the NIHs Helping to End Addiction Long-term (HEAL) Initiative. EPPIC-Net will provide a robust and readily accessible infrastructure for carrying out in depth phenotyping and biomarker studies in patients with specific pain conditions, and the rapid design and performance of high-quality Phase 2 clinical trials to test promising novel therapeutics for pain from partners in academia or industry. Studies will bring intense focus to patients with well-defined pain conditions and high unmet therapeutic needs. EPPIC-Net will consist of one Clinical Coordinating Center (CCC), one Data Coordinating Center (DCC) and approximately 10 specialized clinical centers (hubs). The purpose of this funding opportunity announcement (FOA) is to invite applications for the hubs within EPPIC-Net. A hub will typically be a regional medical center that will actively enroll subjects into clinical trials and studies performed in EPPIC-Net. Each hub should have ready access to patient populations with specific pain conditions and have expertise in characterization of that pain condition. A hub will additionally provide scientific leadership and administrative oversight to its multiple (2-10) satellite sites (spokes). This FOA solicits applications EPPIC-Net Specialized Clinical Centers. Separate FOAs have been issued to solicit applications for the Clinical Coordinating Center (RFA-NS-18-036) and Data Coordinating Center (RFA-NS-18-035). Clinical trials conducted through EPPIC-Net may come from a variety of sources including the HEAL Partnership, as described above, or from separate NIH funding announcements.

Funding Opportunity RFA-NS-19-023 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to invite applications for the Clinical Coordinating Center (CCC) of the Early Phase Pain Investigation Clinical Network (EPPIC-Net). EPPIC-Net will serve as the cornerstone of the NIHs Helping to End Addiction Long-term (HEAL) Partnership. EPPIC-Net will provide a robust and readily accessible infrastructure for carrying out in-depth phenotyping and biomarker studies in patients with specific pain conditions, and the rapid design and performance of high-quality Phase 2 clinical trials to test promising novel therapeutics for pain from partners in academia or industry. Studies will bring intense focus to patients with well-defined pain conditions and high unmet therapeutic needs. EPPIC-Net will consist of one Clinical Coordinating Center (CCC), one Data Coordinating Center (DCC) and approximately 10 specialized clinical centers (Hubs). The CCC will both help design and facilitate the implementation of clinical trials and studies. This FOA solicits applications for EPPIC-Net CCC. Separate FOAs have been issued to solicit applications for the Data Coordinating Center (RFA-NS-18-035) and Specialized Clinical Centers (RFA-NS-18-037). Clinical trials conducted through EPPIC-Net may come from a variety of sources including the HEAL Partnership or from separate NIH funding announcements.

Funding Opportunity RFA-NS-19-024 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to invite applications for the Data Coordinating Center (DCC) of the Early Phase Pain Investigation Clinical Network (EPPIC-Net). EPPIC-Net will serve as the cornerstone of the NIHs Helping to End Addiction Long-term (HEAL) Partnership. EPPIC-Net will provide a robust and readily accessible infrastructure for carrying out in depth phenotyping and biomarker studies in patients with specific pain conditions, and the rapid design and performance of high-quality Phase 2 clinical trials to test promising novel therapeutics for pain from partners in academia or industry. Studies will bring intense focus to patients with well-defined pain conditions and high unmet therapeutic needs. EPPIC-Net will consist of one Clinical Coordinating Center (CCC), one Data Coordinating Center (DCC) and approximately 10 specialized clinical centers (hubs). As the main data manager for pain research in the HEAL Initiative, the EPPIC-Net DCC will host and manage clinical, neuroimaging, biomarker, omics, and preclinical data from EPPIC-Net and other components of the HEAL Initiatives pain research program. The DCC will also make these data and clinical biosamples available to the research community to advance the science of pain. Lastly,the DCC will provide leadership in the statistical design and analysis of EPPIC-Net studies, and the systems and processes for data collection, management, quality assurance and reporting. This FOA solicits applications for the EPPIC-Net Data Coordinating Center (DCC). Separate FOAs have been issued to solicit applications for the Clinical Coordinating Center (RFA-NS-18-036) and Specialized Clinical Centers (RFA-NS-18-037). Clinical trials conducted through EPPIC-Net may come from a variety of sources including the HEAL initiative, as described above, or from separate NIH funding announcements.

Funding Opportunity RFA-AR-19-027 from the NIH Guide for Grants and Contracts. NIH has identified a set of research priorities reflecting urgent unmet needs across the lifespan, areas of promising scientific opportunity, and concrete strategies capable of providing rapid and durable solutions to the opioid crisis including improved understanding of the biological underpinnings of chronic pain and discovery and testing of new non-addictive pain treatments.

Funding Opportunity RFA-AR-19-029 from the NIH Guide for Grants and Contracts. NIH has identified a set of research priorities reflecting urgent unmet needs across the lifespan, areas of promising scientific opportunity, and concrete strategies capable of providing rapid and durable solutions to the opioid crisis including improved

Funding Opportunity RFA-AR-19-026 from the NIH Guide for Grants and Contracts. NIAMS intends to publish a Funding Opportunity Announcement focused on acute and chronic back pain research using novel, inter and multidisciplinary integrated approaches and novel analytics for discovery of disease mechanisms and features for deep patient phenotyping and identification of new targets for intervention.

Negotiable: Paramount Recruitment: Senior Rare Disease Analyst - Genomics London Paramount are working in partnership with Genomics England to expand their team in order to deliver suc London, England

Negotiable: Paramount Recruitment: Clinical Bioinformatician Bioinformatics, Permanent, Rare Diseases and Cancer! Paramount are working in partnership with Genomics England who have successfully completed their 100,000 Genomes Project and are now working with the NHS to create the w London, England

Negotiable: Paramount Recruitment: Senior Scientist Machine Learning - Bioinformatics Senior level, permanent, Immunology! A fantastic new opportunity has become available for a Bioinformatics Scientist specialising in Machine Learning to join a biopharma company in Baden-Wuerttember Baden-Württemberg, Germany

Notice NOT-OD-19-042 from the NIH Guide for Grants and Contracts

Negotiable: Paramount Recruitment: Senior Rare Disease Analyst Bioinformatics, Central London, Permanent! Paramount are working in partnership with Genomics England to expand their team in order to deliver success with the 100,000 Genomes Project. London, England

Notice NOT-OD-19-028 from the NIH Guide for Grants and Contracts

The level of position will be based on years of experience and accomplishments in a bioinformatics, data science, computational biology or computer vision or...
From Marshfield Clinic Health System - Thu, 06 Dec 2018 19:11:20 GMT - View all Marshfield, WI jobs

In bioinformatics, biology, bioengineering, computational biology, or a related scientific discipline. Perform analyses in a accessible manner and to clearly...
From Institute for Systems Biology - Thu, 06 Dec 2018 09:20:10 GMT - View all Seattle, WA jobs

Negotiable: Paramount Recruitment: Senior Rare Disease Analyst Bioinformatics, Central London, Permanent! Paramount are working in partnership with Genomics England to expand their team in order to deliver success with the 100,000 Genomes Project. London, England